Important enough for the trade press though. A little surprised it did not rate an ASX release as it represents one of the ANDA pipeline products. However, have to agree that it will have minimal revenue impact as there are about a dozen other generic companies marketing this product in capsule or tablet dosage forms. The product actually received marketing approval last December and was listed in the Orange Book on 17/12/2019. It did not rate a mention in the ASX Half Yearly, media or investor presentations either. So can see why its 'launch' is not considered market sensitive.
Important enough for the trade press though. A little surprised...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.25 |
Change
-0.150(2.78%) |
Mkt cap ! $426.5M | |||
| Open | High | Low | Value | Volume |
| $5.35 | $5.41 | $5.19 | $1.239M | 231.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $5.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.36 | 1000 | 1 |
View Market Depth
| Last trade - 16.11pm 25/07/2025 (20 minute delay) ? |
| MYX (ASX) Chart |